Regorafenib-Associated Pancreatic Atrophy and Survival Outcomes in Metastatic Colorectal Cancer

Background/Objectives: Regorafenib is a multikinase inhibitor approved for refractory metastatic colorectal cancer (mCRC). VEGF-pathway inhibition may also cause structural changes in normal organs, including pancreatic volume loss. We evaluated pancreatic volume changes during regorafenib therapy and their association with treatment exposure and clinical outcomes. Methods: We retrospectively analyzed 85 of 115 screened patients with mCRC treated with regorafenib at a single center who had contrast-enhanced CT before treatment and at the first response evaluation. Pancreatic atrophy was defined a priori as a ≥10% volume reduction from baseline. Survival was analyzed with a 12-week landmark approach; for OS, landmark and time-dependent Cox models were added. Results: Median pancreatic volume decreased from 54.22 to 50.00 mL (median paired change −5.8%, 95% CI −9.1 to −4.2; p < 0.001), and atrophy developed in 31 patients (36.5%). Atrophy was associated with longer treatment duration (median 149 vs. 92 days; p = 0.001) and higher disease control (58.6% vs. 17.3%; p < 0.001). The conventional PFS comparison favored the atrophy group (5.26 vs. 3.29 months; p = 0.003) but is confounded by guarantee-time bias. In the 12-week landmark population (n = 65), median PFS was 2.50 vs. 1.28 months (log-rank p = 0.046); however, atrophy was not independently associated with PFS (HR 0.68, 95% CI 0.39–1.20; p = 0.181). Median OS was 11.30 vs. 6.74 months (p = 0.271), and atrophy was not independently associated with OS in conventional (HR 0.99, 95% CI 0.60–1.64), landmark (HR 1.05, 95% CI 0.62–1.76), or time-dependent (HR 1.16, 95% CI 0.69–1.94) models. Conclusions: Regorafenib-associated pancreatic atrophy is a measurable imaging finding linked to longer treatment exposure and concurrent disease control. After accounting for guarantee-time bias, it was not independently associated with PFS or OS and should not be regarded as a prognostic biomarker.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-13
DOI
https://doi.org/10.3390/jcm15228897
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Regorafenib-Associated Pancreatic Atrophy and Survival Outcomes in Metastatic Colorectal Cancer

Talat Aykut, Bahattin Engin Kaya, Oğuzhan Yıldız, Cengiz Kadıyoran et al.
3 links
Journal of Clinical Medicine
Colorectal Cancer Treatments and Studies
article

Regorafenib-Associated Pancreatic Atrophy and Survival Outcomes in Metastatic Colorectal Cancer

Talat Aykut, Bahattin Engin Kaya, Oğuzhan Yıldız, Cengiz Kadıyoran, Mehmet Artaç, Murat Araz, İsmail Beypınar, Melek Karakurt Eryılmaz, Ali Fuat Gürbüz
article en

Abstract

Background/Objectives: Regorafenib is a multikinase inhibitor approved for refractory metastatic colorectal cancer (mCRC). VEGF-pathway inhibition may also cause structural changes in normal organs, including pancreatic volume loss. We evaluated pancreatic volume changes during regorafenib therapy and their association with treatment exposure and clinical outcomes. Methods: We retrospectively analyzed 85 of 115 screened patients with mCRC treated with regorafenib at a single center who had contrast-enhanced CT before treatment and at the first response evaluation. Pancreatic atrophy was defined a priori as a ≥10% volume reduction from baseline. Survival was analyzed with a 12-week landmark approach; for OS, landmark and time-dependent Cox models were added. Results: Median pancreatic volume decreased from 54.22 to 50.00 mL (median paired change −5.8%, 95% CI −9.1 to −4.2; p < 0.001), and atrophy developed in 31 patients (36.5%). Atrophy was associated with longer treatment duration (median 149 vs. 92 days; p = 0.001) and higher disease control (58.6% vs. 17.3%; p < 0.001). The conventional PFS comparison favored the atrophy group (5.26 vs. 3.29 months; p = 0.003) but is confounded by guarantee-time bias. In the 12-week landmark population (n = 65), median PFS was 2.50 vs. 1.28 months (log-rank p = 0.046); however, atrophy was not independently associated with PFS (HR 0.68, 95% CI 0.39–1.20; p = 0.181). Median OS was 11.30 vs. 6.74 months (p = 0.271), and atrophy was not independently associated with OS in conventional (HR 0.99, 95% CI 0.60–1.64), landmark (HR 1.05, 95% CI 0.62–1.76), or time-dependent (HR 1.16, 95% CI 0.69–1.94) models. Conclusions: Regorafenib-associated pancreatic atrophy is a measurable imaging finding linked to longer treatment exposure and concurrent disease control. After accounting for guarantee-time bias, it was not independently associated with PFS or OS and should not be regarded as a prognostic biomarker.

Journal of Clinical MedicineVol. 15(22)
Necmettin Erbakan University (TR), Alanya Alaaddin Keykubat Üniversitesi (TR)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon